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Abstract
Osteoblasts/osteocytes are the principle sources of ﬁbroblast
growth factor 23 (FGF23), a phosphaturic hormone, but the
regulation of FGF23 expression during osteoblast develop-
ment remains uncertain. Because 1a,25-dihydroxyvitamin
D3 (1,25(OH)2D3) and inorganic phosphate (Pi) may act as
potent activators of FGF23 expression, we estimated how
these molecules regulate FGF23 expression during rat
osteoblast development in vitro. 1,25(OH)2D3-dependent
FGF23 production was restricted largely to mature cells in
correlation with increased vitamin D receptor (VDR)
mRNA levels, in particular, when Pi was present. Pi
alone and more so in combination with 1,25(OH)2D3
increased FGF23 production and VDR mRNA expression.
Parathyroid hormone, stanniocalcin 1, prostaglandin E2,
FGF2, and foscarnet did not increase FGF23 mRNA
expression. Thus, these results suggest that 1,25(OH)2D3
may exert its largest effect on FGF23 expression/production
when exposed to high levels of extracellular Pi in
osteoblasts/osteocytes.
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Introduction
Inorganic phosphate (Pi) contributes to multiple cell
pathways and processes by acting as a component of
mineralized matrices, nucleic acids and phospholipid bilayers;
as a source of energy in the hydrolysis of ATP; as a substrate
for various kinases/phosphatases; and as a regulator of
intracellular signaling. The 1a,25-dihydroxyvitamin D3
(1,25(OH)2D3)–parathyroid hormone (PTH) axis plays a
major role in phosphate homeostasis, but clinical features of,
for example, vitamin D-resistant rickets suggest the existence
of additional phosphaturic factor(s). Recently, intensive
studies of several such putative factors (e.g. matrix extracellu-
lar phosphoglycoprotein, dentin matrix protein 1 (DMP1),
and ﬁbroblast growth factor 23 (FGF23) have provided new
insights into phosphate homeostasis (Quarles 2003, Qin et al.
2007). Among these molecules, FGF23 has been studied most
extensively in both basic and clinical studies, since it was
identiﬁed as the factor responsible for autosomal dominant
hypophosphatemic rickets (The ADHR Consortium 2000).
More recently, this newest FGF family member has been
shown to be involved in multiple inherited/acquired
hypophosphatemic and chronic kidney disease–mineral
bone disorders (Yu & White 2005).
FGF23 is expressed primarily in bones, most notably in
osteoblasts and osteocytes (Riminucci et al. 2003, Kolek et al.
2005, Yoshiko et al. 2007b). Indeed, analyses of Fgf23-null
(Fgf23
K/K) mice on a Hyp (a mouse model of X-linked
hypophosphatemia with loss-of-function mutations in phos-
phate-regulating gene with endopeptidase activity on the X
chromosome (Phex)) background (Sitara et al. 2006) and
Dmp1
K/K mice (Feng et al. 2006) indicated that osteocytes
are the major sources of FGF23 at least under these
pathological conditions. Klotho, a 130 kDa single trans-
membrane protein having b-glucuronidase activity, appears to
form a complex with FGF23 and FGF receptors to support
FGF23-dependent signaling in target cells (Urakawa et al.
2006, Kurosu et al. 2007). Indeed, FGF23 is released into the
circulation, and it acts on renal proximal tubules to prevent
phosphate reabsorption by suppressing the expression of the
type IIa and type IIc sodium-dependent phosphate cotran-
sporters (NPT2a,c; Larsson et al. 2004). The polypeptide
also suppresses the expression of vitamin D 1a-hydroxylase
(1a(OH)ase) and PTH, resulting in a reduction in serum
1,25(OH)2D3 (Shimada et al. 2004) and PTH (Ben-Dov et al.
2007)levelsrespectively.Giventheseeffects,anexcessofactive
FGF23 in the circulation causes hypophosphatemia with
resultant onset of rickets/osteomalacia (Liu & Quarles 2007).
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FGF23 expression may facilitate the development of
new therapies for abnormal phosphate metabolism
involving FGF23.
1,25(OH)2D3 appears to be a stimulator of FGF23
expression/production in humans (Burnett-Bowie et al.
2009) and rodents (Shimada et al. 2004, Ito et al. 2005,
Kolek et al. 2005, Saito et al. 2005). Klotho
K/K mice show
extremely high serum FGF23 levels with increased serum
1,25(OH)2D3 and Pi, and decreased serum PTH levels
(Yoshida et al. 2002), which are traits that are signiﬁcantly
reversedbyablating1a(OH)aseaswellasKlotho(Ohnishietal.
2009),suggestingthat 1,25(OH)2D3 playsakeyroleinFGF23
production. However, in Dmp1
K/K mice, serum FGF23
levelsarehigh,despitelowserumPiandnormal1,25(OH)2D3
levels (Liu et al. 2008). A contribution of Pi to serum
FGF23 levels has been described in rodent models controlled
by dietary phosphorus under 5/6 nephrectomized conditions
(Saito et al. 2005). Normalization of serum Pi levels by diet
increases serum FGF23 levels invitamin D receptor (Vdr)
K/K
mice exhibiting hypocalcemia and hypophosphatemia
secondary to hyperparathyroidism (Yu et al. 2005).
With respect to in vitro studies, Pi at an optimum
concentration (3 mM) acts synergistically with 1,25(OH)2D3
to increase FGF23 promoter activity as well as endogenous
FGF23 mRNA expression in the K562 human chronic
myelogenous leukemia cell line, but not in the MC3T3-E1
mouseosteoblasticcellline(Itoetal.2005).The1,25(OH)2D3
effectonFGF23mRNAexpressionisobservedinUMR-106
osteosarcoma cells (Kolek et al. 2005, Barthel et al. 2007) and
fetal rat calvarial cells (Yoshiko et al. 2007b). However, Pi
(1–4 mM) alone does not change FGF23 promoter activity in
ROS17/2.8 rat osteosarcoma cells (Liu et al. 2006a). PTH has
also been indicated as a regulator of FGF23; serum FGF23
levels and FGF23 mRNA expression in bones increase in
transgenic mice with parathyroid-targeted overexpression of
the human cyclin D1 oncogene, a model of primary
hyperparathyroidism, and in parathyroidectomized mice
(Kawata et al. 2007). In contrast, PTH decreases FGF23
promoteractivityinROS17/2.8cells(Liuetal.2006a,Barthel
et al. 2007). Taken together, the data indicate a need for
additional studies to clarify whether and how FGF23
expression is regulated during osteoblast development.
Herein, we have used a well-established rat calvaria (RC)
osteoblast developmental model in vitro, and shown that
1,25(OH)2D3 acts predominately in mature cells to increase
FGF23expressioninresponsetohighlevelsofextracellularPi.
Materials and Methods
Reagents
His-tagged human stanniocalcin 1 (STC1) was prepared as
described (Yoshiko et al. 2003). Human FGF2 were obtained
from R&D Systems (Minneapolis, MN, USA). Selective
prostaglandin E receptor subtype EP2 agonist (ONO-AEI-
259; Suzawa et al. 2000) was a gift from Ono Pharmaceutical
Co. (Osaka, Japan). 1,25(OH)2D3 and synthetic PTH1–34
peptide were purchased from BIOMOL International
(Plymouth Meeting, PA, USA) and BACHEM AG (Buben-
dorf, Switzerland) respectively. All other chemicals, unless
otherwise speciﬁed, were purchased from Sigma–Aldrich.
Stock solutions were prepared in an appropriate vehicle and
diluted with a medium (1000 times or more) before use. We
used 1,25(OH)2D3 and foscarnet, a competitive inhibitor of
NPT at 10 nM and 0.5 mM respectively according to our
previous observations (Yoshiko et al. 2007a,b).
Animals
Animal use and procedures were approved by the Committee
of Research Facilities for Laboratory Animal Science,
Hiroshima University.
Cell cultures
Calvariae were obtained from 21-day-old fetal rats as
described (Bellows et al. 1986). Brieﬂy, calvariae were minced
and digested using collagenase (type I) for 10, 20, 30, 50, and
70 min at 37 8C. Cells retrieved from the last four of ﬁve
digestion fractions were separately grown in aMEM
containing 10% fetal bovine serum (HyClone, Logan, UT,
USA) and antibiotics. After 24 h, the cells were recovered,
pooled, and grown in multi-well plates or 35mm dishes
(0.3!10
4/cm
2) in the same medium supplemented addition-
ally with 50 mg/ml ascorbic acid (osteogenic medium). To
obtain osteoblast/osteocyte-rich fractions, cells at day 12 were
treated with collagenase until cells in osteoid-like nodules
were selectively dispersed (Yoshiko et al. 2007a). Recovered
cell suspension was then replated at a high cell density (w5!
10
4/cm
2), and grown in osteogenic medium for a week.
Cells were treated with or without agents including
b-glycerophosphate (bGP) either alone or in different
combinations for 2 days; bGP was also used as an inducer of
matrix mineralization in this model. Medium was changed
every 2–3 days, and cultures were maintained at 37 8Ci na
humidiﬁed atmosphere with 5% CO2.
Measurement of Pi concentrations
Conditioned media were collected, and Pi concentrations
were determined colorimetrically (Phospha-C test, Wako
Pure Chemical Industries Ltd, Osaka, Japan) according to the
manufacturer’s directions.
ELISA
Conditioned media containing cells grown under appropriate
conditions were stored at K80 8C until use. Levels of FGF23
were measured using an FGF23 ELISA kit (Kainos Lab,
Tokyo, Japan) according to the manufacturer’s directions.
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Total RNA was isolated from cells using TRIzol reagent
(Invitrogen) according to the manufacturer’s directions.
cDNA was synthesized from %3 mg of total RNA using
ReverTra Ace (TOYOBO, Osaka, Japan) at 50 8C for 40 min.
Primer sets for rat osteoblast markers and ribosomal L32 as the
internal control are described elsewhere (Yoshiko et al. 2003):
alkaline phosphatase (ALP), 50-GAT AGG CGA TGT CCT
TGC AG-30 and 50-TTA AGG GCC AGC TAC ACC AC-30;
bone sialoprotein, 50-CGC CTA CTT TTA TCC TCC
TCT G-30 and 50-CTG ACC CTC GTA GCC TTC ATA
G-30; osteocalcin (OCN), 50-AAC GGT GGT GCC ATA
GAT GC-30 and 50-AGG ACC CTC TCT CTG CTC
AC-30; osteopontin, 50-AGA GGA GAA GGC GCA TTA
CA-30 and 50-GCA ACT GGG ATG ACC TTG AT-30; and
ribosomal protein L32, 50-CAT GGC TGC CCT TCG
GCC TC-30 and 50-CAT TCT CTT CGC TGC GTA
GCC-30. Primer sets for rat FGF23, VDR, PHEX and
DMP1 were designed using Primer Picking (Primer 3) as
follows: FGF23, 50-TAATAG GGG CCATGA CCA GA-30
and 50-CCT TCC TCT GCA CTC GGT AG-30; VDR,
50-ACA GTC TGA GGC CCA AGC TA-30 and 50-CTG
GTC ATC GGA GGT GAG AT-30; PHEX, 50-CCG AAC
CAG TGA GGC TAT GT-30 and 50-TCA GAG TCC ACA
GAC CAC CA-30; and DMP1, 50-AGT TCG ATG ATG
AGG GGATG-30 and 50-GTC CCT CTG GGC TAT CTT
CC-30. Real-time RT-PCR was carried out using the Light
Cycler system (Light CyclerTM DNA Master SYBR Green
I; Roche Diagnostics) as described earlier (Wang et al. 2008).
To conﬁrm the authenticityof DNA products, each amplicon
was sequenced, and qRT-PCR melting curve analysis was
performed. Controls containing no reverse transcriptase or no
cDNA were also used.
ALP/von Kossa staining
Cells were ﬁxed in neutral buffered formalin for 15 min,
washed, and incubated with AS MX phosphate/blue LB in
0.1 M Tris–HCl (pH 8.3), followed by incubation with 2.5%
silver nitrate solution.
Statistical analysis
Data obtained from at least three samples are expressed as the
meanGS.D., and minimum two independent experiments
were performed. Statistical differences were evaluated by
one-way ANOVA and post hoc Tukey’s test.
Results
FGF23 expression appears to be restricted to osteoblasts and
osteocytes in normal human (Mirams et al. 2004), rat (Yoshiko
et al. 2007b) and Hyp mouse (Liu et al. 2006b) skeletal tissues,
but the expression is low throughout osteoblast development
in non-1,25(OH)2D3-treated RC cells in vitro (Yoshiko et al.
2007b). To determine whether 1,25(OH)2D3 differentially
regulates FGF23 at different osteoblast developmental times,
as it does other genes (Gurlek et al. 2002), we compared the
effect of 1,25(OH)2D3 on FGF23 levels in conditioned media
containing rat calvarial cells at three typical developmental
times/stages: d3 (proliferation stage in primary culture), d9
(differentiation stage in primary culture), s-d7 (cells at d12/
mature stage in primary culture subcultured and grown for an
additional 7 days). Cells in each developmental time window
were either treated or not treated with 1,25(OH)2D3 for
2days in the presence or absence ofbGP, the latter was usedto
stimulate matrix mineralization in the RC model. Based on
the relative levels of DMP1 versus ALP and OCN mRNAs,
we conﬁrmed that cells at d3 were immature, those at d9 were
differentiated, and those at s-d7 were most mature/fully
differentiated (i.e. exhibited osteocyte-like features; Toyosawa
et al. 2001, Kalajzic et al. 2004; Fig. 1A). FGF23 levels of the
cells grown in media without exogenous 1,25(OH)2D3 were
very low at all stages, and treatment with 1,25(OH)2D3
increased FGF23 levels at d9 and s-d7 but not at d3;
1,25(OH)2D3-induced FGF23 levels were highest in s-d7
cultures (Fig. 1B).
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Figure 1 Effect of 1,25(OH)2D3 on FGF23 production during
osteoblast development: proliferation stage (d3), differentiation
stage (d9) and mature osteoblast/osteocyte stage (s-d7). (A) Proﬁling
of osteoblast/osteocyte marker mRNA expression by qRT-PCR. Total
RNA was isolated from cells at each stage, and cDNA was
synthesized and subjected to qRT-PCR. Values are relative to d3 set
at1.0.*P!0.05and**P!0.01comparedwithd3.(B)FGF23levels
in conditioned media determined by an ELISA. Conditioned media
were collected from cell cultures fed with fresh medium for 2 days.
1,25(OH)2D3, 10 nM. *P!0.05 and **P!0.01 compared with d3.
##P!0.01 compared with stage-matched vehicle control (K).
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treated cells at s-d7 with bGP, a substrate known to be
hydrolyzed by ALP in the RC cultures, as described earlier
(bGP washydrolyzedwithin 8 h(Bellows etal. 1992)). In fact,
Pi levels in the medium containing s-d7 (mature) cells treated
with 10 mM bGP for 2 days were comparable to those when
10 mM Pi was added exogenously (Fig. 2A). bGP alone
increased FGF23 levels in the medium, but to a lesser extent
than 1,25(OH)2D3 treatment (Fig. 2B). Cotreatment with
both reagents led to FGF23 levels in the medium that were 3
and 500 times higher than those obtained with 1,25(OH)2D3
alone or bGP alone respectively (Fig. 2B), suggesting that
bGP plus 1,25(OH)2D3 exerted a synergistic effect on FGF23
production. Treatment of s-d7 cells with either bGP or Pi
dose-dependently increased FGF23 levels in the medium; the
maximum effect (6–9 times higher than those obtained with
vehicle alone) was observed at 10 mM in each case (Fig. 2C).
Correspondingly, bGPand Pi nearlyequally increasedFGF23
mRNA expression, but less effectively than 1,25(OH)2D3
(Fig. 2D). In contrast to the effects on FGF23 levels in the
medium (see Fig. 2B and C), combined 1,25(OH)2D3 and
bGP or Pi treatment increased FGF23 mRNA expression
only slightly; however, the effects were abolished by
cotreatment with foscarnet, a competitive inhibitor of NTP
(Fig. 2D). Thus, we concluded that both 1,25(OH)2D3 and Pi
increase FGF23 production in RC osteoblast/osteocyte
cultures, but the effect of 1,25(OH)2D3 is much larger than
that of Pi alone. However, we also established that Pi potently
enhances the effect of 1,25(OH)2D3 on FGF23 production.
Consistent with the results showing that 1,25(OH)2D3
increases FGF23 expression via classical VDR/nuclear
receptor-mediated pathways (Ito et al. 2005, Liu et al.
2006a), we found that VDR mRNA levels in RC cells
were highest in s-d7 cells (Fig. 3A), a temporal pattern that
paralleled the FGF23 expression/production proﬁle in
response to 1,25(OH)2D3 (cf. Fig. 1B). Moreover, treatment
of s-d7 cells with bGP increased VDR mRNA expression,
which was further enhanced by cotreatment with
1,25(OH)2D3 (Fig. 3B). Therefore, we concluded that RC
osteoblasts/osteocytes but not less maturecells produce a large
amount of FGF23 when exposed to 1,25(OH)2D3 con-
comitant with high levels of extracellular Pi. Because serum
FGF23 levels were high in Hyp and Dmp1
K/K mice, even
with low or normal levels of serum Pi and 1,25(OH)2D3,w e
also assessed whether bGP and/or 1,25(OH)2D3 down-
regulate the expression levels of PHEX and DMP1 mRNAs
in s-d7 cells. bGP increased both PHEX and DMP1 mRNA
levels, but it lost the stimulatory effect on PHEX but not on
DMP1 when combined with1,25(OH)2D3 (Fig. 3C and D).
Because PTH is a stimulator of FGF23 expression in a
mouse model of primary hyperparathyroidism as well as in
parathyroidectomized mice (Kawata et al.2 0 0 7 ), we
examined whether PTH increases FGF23 mRNA expression
in the RC model. In addition, we tested anumberof potential
mediators of PTH actions/pathways and factors involved in
matrix mineralization. STC1 is suggested to be involved in
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Figure 2 Effects of bGP or Pi on FGF23 production/expression in
the presence or absence of 1,25(OH)2D3 in s-d7 cells (mature
osteoblasts/osteocytes).(A) Piconcentrationsin theculturemediain
s-d7 cells treated with or without bGP or Pi (10 mM each) for 24 h.
No cell indicates Pi concentrations without cells. *P!0.05
compared with vehicle control (K). Pi concentrations were
measured colorimetrically. (B) Effect of 10 mM bGP and/or 10 nM
1,25(OH)2D3 on FGF23 levels in conditioned media. *P!0.05 and
**P!0.01 compared with vehicle control (K).
##P!0.01
compared with 1,25(OH)2D3 alone. (C) Dose-dependent effect of
bGP or Pi on FGF23 levels in conditioned media. *P!0.05 and
**P!0.01 compared with vehicle control (K). (A–C) Conditioned
media were collected as described in Fig. 1. (B and C) FGF23 levels
were assayedas describedin Fig. 1. (D) Effect ofbGPor Pi on FGF23
mRNA expression in the presence of 1,25(OH)2D3. 1,25(OH)2D3,
10 nM; foscarnet, 0.5 mM. qRT-PCR was performed as described in
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osteoblast cultures (Yoshiko et al. 2003). Prostaglandin E2
(PGE2)actsdiverselyonosteoblasts,forexample,byincreasing
receptor activator of NF-kB ligand (RANKL) secretion (Tat
et al. 2008). FGF2 inhibits matrix mineralization through the
regulation of Pi handling in the MC3T3-E1 mouse calvaria
osteoblastic cell line (Hatch et al. 2005). Like foscarnet that
decreases NPT activity (Yoshiko et al. 2007a), some of these
factorsincreaseordecreaseNPTactivityinosteoblasts(see,for
example, Selz et al. 1989, Veldman et al. 1998, Yoshiko et al.
2003). We also examined forskolin (not shown) and the
prostaglandin E receptor subtype EP2, which, like PTH,
activates the adenylate cyclase/protein kinase A (PKA)
pathway(Narumiya&FitzGerald2001).However,incontrast
to 1,25(OH)2D3, none of these factors increased FGF23
mRNA expression in s-d7 cells in the presence of bGP
(Fig. 4A). Notably, there was also no correlation between
FGF23 levels and the changes in mineralization elicited byany
of these reagents (Fig. 4B and C).
Discussion
By using the RC cell culture model, we have shown that
1,25(OH)2D3 acts mostly on mature cells to increase FGF23
secretion/mRNA expression during osteoblast development.
bGP, apparently via its ability to increase extracellular Pi,
enhances the 1,25(OH)2D3 effect on FGF23 secretion, but
has only a small effect on its own. The upregulation of VDR
mRNA expression in mature cells in response to cotreatment
with 1,25(OH)2D3 and bGP provides one plausible expla-
nation for the speciﬁcity of their effects on mature
osteoblast/osteocyte stages. On the other hand, PTH and
other factors involved in NPT activity and/or the PKA
pathway did not alter FGF23 mRNA expression. These
results suggest that 1,25(OH)2D3 may act speciﬁcally on
osteoblasts/osteocytes exposed to high levels of extracellular
Pi to increase FGF23 production.
Although recent expression proﬁling of RNA from cortical
bones of Hyp mice points towards a potential relationship
between FGF23 mRNA expression and molecules involved
in Wnt signaling and the FGF family members FGF1 and
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most unequivocal stimulators of FGF23 expression/
production (Ito et al. 2005) (see Introduction). However,
FGF23 responses to either 1,25(OH)2D3 or Pi are not
identical across different osteoblastic/non-osteoblastic cell
models (Ito et al. 2005, Kolek et al. 2005, Liu et al. 2006a,
Barthel et al. 2007, Yoshiko et al. 2007b). For example, in
some genetically engineered mouse strains, serum FGF23
levels do not respond to increases or decreases in
1,25(OH)2D3 and Pi levels (Yu et al. 2005, Liu et al. 2008);
similar discrepancies exist among culture models (Ito et al.
2005, Liu et al. 2006a) (cf. Introduction). Our data show that
there is a synergistic effect of 1,25(OH)2D3 and Pi on FGF23
production, but that the effect is much less on FGF23 mRNA
expression. Thus, we speculate that in contrast to
1,25(OH)2D3, which enhances transcriptional activation of
FGF23 (Barthel et al. 2007), Pi may be involved in post-
translational control of FGF23. Further analysis of the several
signaling pathways activated in osteoblasts by Pi uptake (Beck
2003)i sn e e d e dt oe l u c i d a t eh o wP ic o n t r i b u t e st o
1,25(OH)2D3-induced FGF23 production. Differences in
the levels of other systemic and local factors or serum
components that participate in Pi homeostasis may also
contribute to the variations observed in Pi, 1,25(OH)2D3 and
PTH effects on FGF23 expression. These include, for
example, factors associated with DMP1 (Feng et al. 2006),
PHEX (Liu et al. 2006b) or Klotho as observed in osteoblasts
from Klotho mutant mice (Kawaguchi et al. 1999). It is also
worthnotingthatwedidnotdetectdownregulationofPHEX
andDMP1concomitant withincreasedFGF23production, as
observedinHypandDmp1-nullmice.However,theincreased
PHEX mRNA levels, but not DMP1 mRNA levels, induced
by bGP were completely abolished by cotreatment with
1,25(OH)2D3 in our model, which areeffects that will require
further assessment. In this regard, it is interesting that the Hyp
bone phenotype is fully rescued by crossing Hyp mice with
PHEX transgenic mice, despite FGF23 expression remaining
high in bones and uncorrected hypophosphatemia (Erben
et al. 2005). DMP1 decreases 1,25(OH)2D3-induced FGF23
mRNA expression in UMR cells (Samadfam et al. 2009).
Klotho is not expressed in osteoblasts (Takeshita et al. 2004).
Thus, our data, taken together with the previous studies
(Takeshita etal.2004,Erbenetal.2005,Samadfametal.2009),
support the view that neither PHEX, DMP1 nor Klotho is
directly involved in the effect of bGP and/or 1,25(OH)2D3
on FGF23 production/expression.
Our results showing that the magnitude of FGF23 levels in
response to 1,25(OH)2D3 varies markedly during osteoblast
development may also explain, at least in part, the diverse
responses to 1,25(OH)2D3,P ia n d / o ro t h e rf a c t o r si n
functionally and phenotypically different osteoblastic models.
Our results are also consistent with in vivo data showing
developmental stage-associated differences in the intensity of
FGF23 expression by immunohistochemistry and in situ
hybridization (Riminucci et al. 2003, Yoshiko et al. 2007b)
and with the results of Fgf23-deﬁcient eGFP reporter activity
in Hyp mice (Liu et al. 2006b).
We reported that not only 1,25(OH)2D3 (Yoshiko et al.
2007b) but also adenoviral overexpression of FGF23 (Wang
et al. 2008) inhibits mineralization in osteoid-like nodules
when bGP is present in the RC cell model. Osteoblasts may
be exposed to high levels of extracellular Pi during bone
resorption and formation, and Pi uptake via NPT3 in
osteoblasts may be crucial for matrix mineralization (Suzuki
et al. 2006, Yoshiko et al. 2007a). However, old rats over-
expressing POU class 1 homeobox 1 via the b-actin promoter
exhibit a decrease in bone mineral density with disruption of
mineral metabolism (Suzuki et al. 2010). Thus, imbalances in
serum levels of either 1,25(OH)2D3 and Pi or both may lead
to an overproduction of FGF23. PTH and other factors are
capable of regulating serum 1,25(OH)2D3 or Pi levels
(Wortsman et al. 1986, Hoppe et al. 1991, Murer et al.
1996, Nakajima et al. 2009) whether FGF23 is involved or
not. Further studies are needed to dissect these pathways.
In any case, our previous data showing the signiﬁcance of Pi
handling by osteoblasts (Yoshiko et al. 2007a) suggest that
Pi levels not only in the serum but also in the bone
microenvironment may be crucial for FGF23 expression/
production. Our data on the expression pattern of VDR also
supporttheimportance ofthemicroenvironment.Inanycase,
the mechanism(s) underlying the ability of Pi and
1,25(OH)2D3 to act cooperatively to increase FGF23
expression/production is unclear. However, taken together
with the combined effect of 1,25(OH)2D3 and Pi on FGF23
promoter activity in K562 cells (Ito et al. 2005), it seems likely
that the mechanisms are not restricted to osteoblasts/
osteocytes. In this regard, VDR mRNA levels are increased
in K562 cells treated with 1,25(OH)2D3, but not in those
treated with Pi (Ito et al. 2005). Thus, intracellular Pi levels in
particularcellssuchasosteoblasts/osteocytesmayplayacritical
role in 1,25(OH)2D3-dependent events. Collectively, the data
support that FGF23 may act as a phosphaturic factor and/or
an inhibitor of bone mineralization under the inﬂuence of
extracellular Pi and 1,25(OH)2D3 locally and systemically.
In summary, the stimulatory effects of 1,25(OH)2D3 on
FGF23 mRNA expression/production were observed
primarily in mature osteoblasts exposed to high levels of
extracellular Pi in the RC cell culture model. VDR mRNA
expression was also upregulated in an osteoblast develop-
mental stage-speciﬁc manner, and expression was further
increased by 1,25(OH)2D3 and extracellular Pi. However,
similar to what has been reported in previous in vitro
experiments (Liu et al. 2006a), we found no stimulatory
effect of either PTH or other molecules known or thought to
be downstream of PTH and/or Pi uptake on FGF23 mRNA
expression, suggesting that PTH is not a direct stimulator of
FGF23 expression at least in cultured RC cells. Thus, we
conclude that 1,25(OH)2D3 acts predominately in osteo-
blasts/osteocytes under conditions of high levels of extra-
cellular Pi to increase FGF23 production in the RC cell
culture model, an observation worth further evaluation.
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